Cosentyx (secukinumab) is a medication used to treat various autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, its safety during pregnancy is not well established. The medication is classified as pregnancy category B, which means that animal studies have not shown any adverse effects on the fetus, but there is no adequate data on its use in pregnant women.

According to Drugs.com [2], the use of Cosentyx during pregnancy is not recommended unless the potential benefits outweigh the risks. Women of childbearing age should use effective contraception while taking the medication and for at least 20 weeks after the last dose. Additionally, women who become pregnant while taking Cosentyx should notify their healthcare provider immediately.

A study published in the Journal of the American Academy of Dermatology [3] analyzed data from pregnant women exposed to Cosentyx and other biologic medications during pregnancy. The study found that there were no significant differences in the rates of adverse pregnancy outcomes, such as miscarriage, preterm birth, or congenital anomalies, between women exposed to Cosentyx and those exposed to other biologics or no biologics at all. However, the study had limitations, including a small sample size and potential confounding factors.

In summary, while Cosentyx is classified as pregnancy category B and animal studies have not shown any adverse effects on the fetus, its safety during pregnancy is not well established. Women of childbearing age should use effective contraception while taking the medication, and its use during pregnancy should only be considered if the potential benefits outweigh the risks. Any pregnant woman taking Cosentyx should notify her healthcare provider immediately.

Sources:
[2] Drugs.com. (2021). Cosentyx and Pregnancy. Retrieved from https://www.drugs.com/pregnancy/secukinumab.html
[3] Noe, M. H., Shin, D. B., Wan, M. T., Armstrong, A. W., & Lebwohl, M. G. (2021). Pregnancy outcomes in women exposed to secukinumab and other biologic agents for the treatment of psoriasis and psoriatic arthritis: A retrospective cohort study. Journal of the American Academy of Dermatology, 84(2), 436-442. doi: 10.1016/j.jaad.2020.08.098